&lt;p&gt;Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma&lt;/p&gt;

Peng, Li; Liang, Yanling; Zhong, Xinxin; Liang, Zhiman; Tian, Yuan; Li, Shuji; Liang, Jingxue; Wang, Ransheng; Zhong, Yuqi; Shi, Yusheng; Zhang, Xingmei

doi:10.2147/ijn.s238206

Cited by 59 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…U2, thanks to a thiol group, was conjugated to a gold nanoparticle (AuNPs) through an Au-S bond. U2-AuNP inhibited the activation of EGFRvIII, affected U87-EGFRvIII cell proliferation and invasion, and increased the survival of GBM-bearing mice [ 37 ].…”

Section: Resultsmentioning

confidence: 99%

The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature

Nuzzo

Brancato

Affinito

et al. 2020

Cancers

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most lethal primary brain tumor of the central nervous system in adults. Despite advances in surgical and medical neuro-oncology, the median survival is about 15 months. For this reason, initial diagnosis, prognosis, and targeted therapy of GBM represent very attractive areas of study. Aptamers are short three-dimensional structures of single-stranded nucleic acids (RNA or DNA), identified by an in vitro process, named systematic evolution of ligands by exponential enrichment (SELEX), starting from a partially random oligonucleotide library. They bind to a molecular target with high affinity and specificity and can be easily modified to optimize binding affinity and selectivity. Thanks to their properties (low immunogenicity and toxicity, long stability, and low production variability), a large number of aptamers have been selected against GBM biomarkers and provide specific imaging agents and therapeutics to improve the diagnosis and treatment of GBM. However, the use of aptamers in GBM diagnosis and treatment still represents an underdeveloped topic, mainly due to limited literature in the research world. On these bases, we performed a systematic review aimed at summarizing current knowledge on the new promising DNA and RNA aptamer-based molecules for GBM diagnosis and treatment. Thirty-eight studies from 2000 were included and investigated. Seventeen involved the use of aptamers for GBM diagnosis and 21 for GBM therapy. Our findings showed that a number of DNA and RNA aptamers are promising diagnostic and therapeutic tools for GBM management.

show abstract

Section: Resultsmentioning

confidence: 99%

The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature

Nuzzo

Brancato

Affinito

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Not significant, n.s. glioblastoma cell lines, particularly: U87, U87-EGFRvIII, U251, T98G, or U138 [38,39,40]. Absence of gold nanoparticles effects on tumor cells growth may come from their low uptake into the cells.…”

Section: Discussionmentioning

confidence: 99%

Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice

Silva

Colli

et al. 2020

Heliyon

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most devastating malignant primary brain tumor known. Life expectance is around 15 months after diagnosis. Several events contribute to the GBM progression such as uncontrolled genetic cancer cells proliferation, angiogenesis (mostly vascular endothelial growth factor (VEGF)mediated), tissue invasion, glioma stem cell activity, immune system failure, and a hypoxic and inflammatory tumor microenvironment. Tumor cells antiproliferative effect of 20 nm citrate-covered gold nanoparticles (cit-AuNP) has been reported, along with anti-inflammatory and anti-oxidative effects. We aimed to test whether either chronic treatment with 20 nm cit-AuNP or anti-VEGF antibody (Ig)-covered AuNP could reduce GBM progression in mice. Main methods: Effect of the gold nanoparticles on the GL261 glioblastoma cells proliferation in vitro, and on the GL261-induced glioblastoma cell growth in C57BL/6 mice in vivo were tested. Besides, fluorophore-conjugated gold nanoparticles penetration through the GL261 plasma cell membrane, gold labelling in brain parenchyma of glioblastoma-carrying mice, and VEGF expression into the tumor were evaluated. Key findings: We observed cit-AuNP did no change the GL261 cells proliferation. Similarly, we demonstrated chronic treatment with either cit-AuNP or anti-VEGF Ig-covered AuNP did not modify the GL261 cells-induced GBM progression in mice. By the end, we showed AuNPs did not trespass in appreciable amount both the GL261 plasma cell membrane and the tumoral blood brain barrier (BBB), and did not change the VEGF expression into the tumor. Significance: 20 nm cit-AuNP or anti-VEGF Ig covered-AuNP are not good tools to reduce GBM in mice, probably because they do not penetrate both tumor cells and BBB in enough amount to reduce tumor growing.

show abstract

“…Among noble metal inorganic nanoparticles, gold nanoparticles (AuNPs) are characterized by easy modification, controllable diameters, and large surface/volume ratios, and are one of the most ideal nanomedicine materials for GBM therapy [ 131 ]. The controlled size of AuNPs makes it easily cross the BBB, but its clinical application is limited by lack of targeting ability [ 131 , 132 ].…”

Section: Current Nanocarriers and Nanocarrier-associated Strategiementioning

confidence: 99%

Section: Current Nanocarriers and Nanocarrier-associated Strategiementioning

confidence: 99%

“…Recently, a DNA aptamer selected from a large random single-stranded DNA has been prepared to target EGFRvIII of GBMs [ 132 ]. The targeting efficiency of aptamer is further enhanced by entrapped into AuNPs through a gold-sulfur covalent bond [ 132 ]. The aptamer-AuNP complexes have been demonstrated as a new type of drug candidate for GBM therapy because they showed efficient antitumor effects in vivo and in vitro inhibition of tumor proliferation [ 132 ].…”

Section: Current Nanocarriers and Nanocarrier-associated Strategiementioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update

Hsu

Chu

Liao

et al. 2021

Cancers

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and malignant brain tumor with poor prognosis. The heterogeneous and aggressive nature of GBMs increases the difficulty of current standard treatment. The presence of GBM stem cells and the blood brain barrier (BBB) further contribute to the most important compromise of chemotherapy and radiation therapy. Current suggestions to optimize GBM patients’ outcomes favor controlled targeted delivery of chemotherapeutic agents to GBM cells through the BBB using nanoparticles and monoclonal antibodies. Nanotechnology and nanocarrier-based drug delivery have recently gained attention due to the characteristics of biosafety, sustained drug release, increased solubility, and enhanced drug bioactivity and BBB penetrability. In this review, we focused on recently developed nanoparticles and emerging strategies using nanocarriers for the treatment of GBMs. Current studies using nanoparticles or nanocarrier-based drug delivery system for treatment of GBMs in clinical trials, as well as the advantages and limitations, were also reviewed.

show abstract

<p>Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma</p>

Cited by 59 publications

References 44 publications

The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature

The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature

Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice

Nanotechnology and Nanocarrier-Based Drug Delivery as the Potential Therapeutic Strategy for Glioblastoma Multiforme: An Update

Contact Info

Product

Resources

About